Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
暂无分享,去创建一个
R. Herbst | D. Rimm | Joseph K. McLaughlin | Gang Han | K. Schalper | Daniel E. Carvajal-Hausdorf | V. Pelekanou | Jamaal A Rehman | V. Velcheti | P. LoRusso | D. Carvajal-Hausdorf | Jamaal Rehman | J. McLaughlin
[1] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[2] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[3] P. Loke,et al. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Nishimura,et al. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.
[5] A. Qattan,et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.
[6] G. Freeman,et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.
[7] N. Xu,et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. , 2006, Acta histochemica.
[8] A. Mackensen,et al. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.
[9] J. Allison,et al. The B7 Family and Cancer Therapy: Costimulation and Coinhibition , 2007, Clinical Cancer Research.
[10] 野見 武男. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer , 2007 .
[11] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[12] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[13] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.
[14] R. Nurieva,et al. Yin–Yang of costimulation: crucial controls of immune tolerance and function , 2009, Immunological reviews.
[15] Yun Li,et al. gp96与免疫相关基因CTLA-4、CD8在肺癌组织芯片中的表达及意义 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[16] T. Okazaki,et al. Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma , 2010, Cancer.
[17] Amal Hasan,et al. Therapeutic targeting of B7-H1 in breast cancer , 2011, Expert opinion on therapeutic targets.
[18] C. Mu,et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation , 2011, Medical oncology.
[19] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[20] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[21] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[22] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[23] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[24] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[25] J. Sosman,et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. , 2013 .
[26] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[27] Lieping Chen,et al. Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.
[28] David C. Smith,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Herbst,et al. Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.
[30] M. Dolled-Filhart,et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). , 2014 .
[31] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[32] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[33] R. Herbst,et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.
[34] J. Madore,et al. PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.
[35] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[37] M. Jakopović,et al. Immunotherapy in the treatment of non-small cell lung cancer , 2017 .